Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 9, 2014, Pages 1019-1025

  Dharmadhikari, Ashwin S ^a   Mphahlele, M ^b   Venter, K ^b   Stoltz, A ^c   Mathebula, R ^b   Masotla, T ^b   Van Der Walt, M ^b   Pagano, M ^d   Jensen, P ^e   Nardell, E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF PRETORIA   (South Africa)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Extensively drug resistant tuberculosis; Impact of treatment; Multidrug resistant tuberculosis; Transmission

Indexed keywords

ETHAMBUTOL; ETHIONAMIDE; KANAMYCIN; LEVOFLOXACIN; PROTIONAMIDE; TUBERCULOSTATIC AGENT;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG SENSITIVITY; EXHAUST GAS; FEMALE; GUINEA PIG; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; SPUTUM SMEAR; TREATMENT DURATION; TUBERCULIN TEST; WARD; ADOLESCENT; ANIMAL; CROSS INFECTION; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; SPUTUM; TIME FACTOR; TRANSMISSION; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AIR MICROBIOLOGY; ANIMALS; ANTITUBERCULAR AGENTS; CROSS INFECTION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; GUINEA PIGS; HUMANS; INFECTION CONTROL; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; SPUTUM; TIME FACTORS; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84906654194     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0834     Document Type: Article

References (32)

1. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. Geneva, Switzerland: WHO, 2012.
2. World Health Organization. WHO policy on TB infection control in health care facilities, congregate settings and households. Geneva, Switzerland: WHO, 2009.
3. Gelmanova I Y, Keshavejee S, Golubchikova V T, et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ 2007; 85: 703-711.
4. Gandhi N R, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
5. Fitzpatrick F K, Floyd K. A systematic review of the cost and cost-effectivenes of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics 2012; 30: 63-80.
6. Mukherjee J S, Rich M L, Socci A R, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004; 363: 474-481.
7. Directorate for Drug-resistant Tuberculosis, TB & HIV, Chief Directorate for TB Control and Management. Multidrug-resistant tuberculosis. A policy framework on decentralised and deinstitutionalised management for South Africa. Durban, South Africa: Department of Health, 2010.
8. Carvalho A C, Migliori G B, Cirillo D M. Tuberculosis in Europe: a problem of drug resistance or much more? Expert Rev Respir Med 2010; 4: 189-200.
9. Loveday M, Wallengren K, Voce A, et al. Comparing early treatment outcomes of MDR-TB in decentralised and centralised settings in KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2012; 16: 209-215.
10. Nardell E, Dharmadhikari A. Turning off the spigot: reducing drug-resistant tuberculosis transmission in resource-limited settings. Int J Tuberc Lung Dis 2010; 14: 1233-1243.
11. Kanjee Z, Catterick K, Moll A P, Amico K R, Friedland G H. Tuberculosis infection control in rural South Africa: survey of knowledge, attitude and practice in hospital staff. J Hosp Infect 2011; 79: 333-338.
12. Frieden T R, Fujiwara P I, Washko R M, Hamburg M A. Tuberculosis in New York City - turning the tide. N Engl J Med 1995; 333: 229-233.
13. Jensen PA, Lambert L A, Iademarco M F, Ridzon R. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health care settings, 2005. MMWR Recomm Rep 2005; 54: 1-141.
14. Dharmadhikari A S, Basaraba R J, Van Der Walt M L, et al. Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis. Tuberculosis (Edinb) 2011; 91: 329-338.
15. Rüsch-Gerdes S, Pfyffer G E, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006; 44: 688-692.
16. Andrews R H, Devadatta S, Fox W, Radhakrishna S, Ramakrishnan C V, Velu S. Prevalence of tuberculosis among close family contacts of tuberculosis patients in south India and influence of segregation of the patient on the early attack rate. Bull World Health Organ 1960; 23: 463-510.
17. Crofton J. The contribution of treatment to the prevention of tuberculosis. Bull Int Union Tuberc 1962; 32 (2): 643-653.
18. Brooks S M, Lassiter N L, Young E. A pilot study concerning the infection risk of sputum positive with tuberculosis patients on chemotherapy. Am Rev Respir Dis 1973; 108: 799-804.
19. Gunnels J, Bates J, Swindoll H. Infectivity of sputum positive tuberculosis patients on chemotherapy. Am Rev Respir Dis 1974; 109: 323.
20. Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: the effects of chemotherapy. Tubercle 1976; 57: 275-299.
21. Telzak E E, Fazal B A, Pollard C L, Turett G S, Justman J E, Blum S. Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis [see Comments]. Clin Infect Dis 1997; 25: 666-670.
22. Menzies D. Effect of treatment on contagiousness of patients with active pulmonary tuberculosis. Infect Control Hosp Epidemiol 1997; 18: 582-586.
23. Fitzwater S P, Caviedes L, Gilman R H, et al. Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy. Clin Infect Dis 2010; 51: 371-378.
24. Riley R L, Mills C C, O'Grady F, Sultan L U, Wittstadt F, Shivpuri D N. Infectiousness of air from a tuberculosis ward. Ultraviolet irradiation of infected air: comparative infectiousness of different patients. Am Rev Respir Dis 1962; 85: 511-525.
25. Riley R L Mills C C, Nyka W, et al. Aerial dissemination of pulmonary tuberculosis: a two-year study of contagion in a tuberculosis ward: 1959. Am J Epidemiol 1995; 142: 3-14.
26. Escombe A R, Moore D A, Gilman R H, et al. The infectiousness of tuberculosis patients coinfected with HIV. PLOS MED 2008; 5: e188.
27. Fennelly K P, Jones-Lopez E C, Ayakaka I, et al. Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2012; 186: 450-457.
28. van Geuns H A, Meijer J, Styblo K. Results of contact examination in Rotterdam, 1967-1969. Bull Int Union Tuberc 1975; 50 (1): 107-121.
29. Fennelly K P. Variability of airborne transmission of Mycobacterium tuberculosis: implications for control of tuberculosis in the HIV era. Clin Infect Dis 2007; 44: 1358-1360.
30. Glynn J R, Whiteley J, Bifani P J, Kremer K, van Soolingen D. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review. Emerg Infect Dis 2002; 8: 843-849.
31. Loudon R G, Bumgarner L R, Coffman G K. Isoniazid and the survival of tubercle bacilli in airborne droplet nuclei. Am Rev Respir Dis 1969; 100: 172-176.
32. Voskuil M I, Bartek I L, Visconti K, Schoolnik G K. The response of mycobacterium tuberculosis to reactive oxygen and nitrogen species. Front Microbiol 2011; 2: 105.